-
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)
Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
5 étapes pour choisir une protéine de contrôle validée en laboratoire(Post)Utilisez une coloration protéine totale, comme le Ponceau S, quand vos traitements risquent de faire varier l’expression des protéines de ménage. Sinon, une protéine housekeeping validée pour votr
Aide protocole ELISA : le guide sandwich pas à pas(Post)Aide protocole ELISA : le guide sandwich pas à pas Voici un protocole ELISA sandwich reproductible et prêt à l’emploi, plus les variantes et contrôles indispensables pour l’obtenir du premier coup. I
PD-1 Blockade in B-Cell Lymphomas: A Comprehensive Overview(Post)Understanding PD-1 Blockade in B-Cell Lymphomas Understanding PD-1 Blockade in B-Cell Lymphomas Introduction The programmed cell death prote
ELISA-Kalibrierung mit 4PL: Laborcheckliste, Kontrollen und Hilfe(Post)ELISA-Kalibrierung mit 4PL: Laborcheckliste, Kontrollen und Hilfe Für symmetrische ELISA-Standardkurven ist das 4-Parameter-logistische Modell (4PL) der praxisgerechte Standard. Starte mit 4PL, prüfe
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars(Post)Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Anti-Angiogenics Do Not Starve Tumours. They Open Them.(Post)Anti-angiogenic therapy does not work by starving tumours, and the trials that assumed it did are the reason the field spent a decade disappointed. Cutting off the blood supply was the original pitch
How to Choose a Secondary Antibody(Post)The selection of a secondary antibody is a critical step in the experimental design of various immunodetection methods, including Western Blot, ELISA, immunohistochemistry (IHC), and immunofluores
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Six étapes pour un protocole ELISA sandwich reproductible en laboratoire(Post)Le protocole ELISA sandwich standard suit six étapes: revêtement du puits avec l’anticorps de capture, blocage, incubation des standards et échantillons, ajout de l’anticorps de détection, puis du
Cancer & Tumour Suppressors – Mini Review(Post)Cancer DevelopmentCancer is a group of diseases that involves abnormal cell growth resulting in malignant tumours/ malignant neoplasms. Cancer is a leading cause of morbidity, with 14 million ne
Spotlight on Mitochondria(Post)Throughout my graduate and postgraduate studies I have been really intrigued and fascinated by the mitochondria, the organelle that keeps all of us running everyday! The more I learn about
PD-1 & PD-L1 Inhibitors(Post)PD-1 & PD-L1 interaction between T-cells and tumour cells. What are PD-1 and PD-L1? PD-1, also known as programmed cell death 1, is a receptor expressed on t
ELISA Troubleshooting: High %CV at Low Standards(Post)QUICK ANSWER On a Human I-FABP/FABP2 ColorStep ELISA, the top of the standard curve looked perfect while the three lowest standards showed duplicate %CVs of 37–450% — because their op
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
Polatuzumab: Redefining Targeted Therapies in B-Cell Lymphoma(Post)What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel
Sofort anwendbar: Antigenretrieval für die IHC, Laborstartwert 120 °C(Post)Beginnen Sie standardmäßig mit HIER (Heat-Induced Epitope Retrieval); PIER reservieren Sie für spezifische Antigene oder Fälle, in denen HIER nachweislich versagt. Puffer-pH entscheidet dabei oft
Understanding T Cell Fatigue: Implications for Immune Function and Therapeutic Interventions(Post)T cells are central players in adaptive immunity, responsible for recognizing and eliminating infected or aberrant cells. Upon encountering antigens, T cells undergo clonal expansion and differ